Your prediction
Pros and Cons of Amp Ltd. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amp Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amp Ltd. | 0.760% | 0.769% | 27.184% | 48.023% | 27.184% | 103.101% | 101.538% |
| National Australia Bank | 0.770% | 2.567% | 11.102% | 21.157% | 9.370% | 56.559% | 58.974% |
| Commonwealth Bank Australia | -2.510% | 1.582% | 9.529% | 14.502% | 21.805% | 84.113% | 75.247% |
| Macquarie Group Ltd | 0.950% | 2.021% | 3.805% | 34.533% | 39.169% | 55.308% | 65.136% |
News
Ardagh Metal Packaging Q2 Earnings Call Highlights
Key Points
- Interested in Ardagh Metal Packaging S.A.? Here are five stocks we like better.
- Ardagh Metal Packaging raised full-year 2026 adjusted EBITDA guidance to $775 million-$790 million
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
Key Points
- Interested in Amphastar Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amphastar is shifting its strategy from complex generics toward proprietary drugs and
Pennon Group H2 Earnings Call Highlights
Key Points
- Interested in Pennon Group Plc? Here are five stocks we like better.
- Pennon returned to profitability in 2025/2026, with EBITDA up 55% and underlying operating profit more than